1 Min Read
May 28 (Reuters) - Novimmune SA (IPO-NOVI.S):
* FDA ACCEPTS EMAPALUMAB BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW Source text: bit.ly/2lagxU7 Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.